rTMS in Older Adults With MCI and AUD
Key facts
- Who runs it
- Medical University of South Carolina
- Where
- Charleston, United StatesSee the 2 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 35 people, planned
- Started
- 1 Nov 2023
- Expected to end
- 30 Nov 2026
- Type of study
- Interventional
- Treatments tested
- Active, Open Label iTBS-rTMS
- Record updated
- 17 September 2026
Who can take part
- Age
- 60 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Age 60-85
- English as a first/primary language
- Current alcohol use disorder
- Alcohol consumption of at least 4 heavy drinking days (defined as ≥ 4 drinks for women and ≥ 5 for men) per week during the 30-days prior to enrolling
- Meets actuarial neuropsychological criteria for MCI: ≥2 impaired scores within one cognitive domain, or ≥1 impaired scores in ≥3 domains, where an impaired score is defined as ≤16th percentile using demographically-corrected norms
- Not pregnant (will administer pregnancy test to confirm)
- Functional visual and auditory acuity to complete all assessments
Who cannot take part
- Prior diagnosis of Dementia or Major Neurocognitive Disorder per NIA-AA or DSM-5 criteria, and TICS ≤ 22 suggestive of dementia
- Daily/weekly anticholinergic or sedative use. Stimulants may be allowed pending investigator review. Cholinesterase inhibitors, NMDA receptor antagonists, and antidepressants are allowed if on a stable regimen of 4 weeks prior to enrollment
- Enrolled in a clinical trial or has received an investigational medication or device in the last 30 days
- Current substance use disorder other than AUD or nicotine use disorder, bipolar disorder, or schizophrenia spectrum or other psychotic disorder
- History of significant or unstable condition/s that may impact cognition such as significant cardiac, cerebrovascular, or metabolic disease, developmental disorder, or other neurologic disease (e.g. movement disorder, moderate to severe brain injury, seizures)
- MRI and TMS contraindications (e.g. implants, claustrophobia, conditions/treatments that lower seizure threshold, taking medications that have short half-lives, no identifiable motor threshold)
- Pregnant (will administer pregnancy test to confirm)
Where in United States
- Medical Univeristy of South CarolinaCharleston, United States
- Medical University of South CarolinaCharleston, United States
About the trial
What the trial wants to find out
Alcohol misuse is a risk factor for early onset cognitive impairment, contributing to 10% of early onset dementia, with risk corresponding to consumption. Additionally, continued drinking risks worsening cognitive decline and dementia progression, while worsening cognitive impairment contributes to drinking escalation. Repetitive transcranial magnetic stimulation (rTMS) has been shown to improve cognition in Alzheimer's Disease and Related Dimentias (ADRD) and separately reduce heavy drinking in alcohol use disorder. Our objective is to optimize rTMS for simultaneous mitigation of both drinking and cognitive dysfunction in older adults.
The group in the trial
- Active, Open Label iTBS-rTMSTreatment being tested
Individuals will receive 10 sessions of iTBS-rTMS per day, 5 days per week for one week (50 sessions total). All will undergo clinical assessments and brain MRI at pre-treatment and at 1-week post-treatment, and clinical assessments at 4-weeks post-treatment. Weekly post-treatment online self-report assessments will be collected up to four weeks. Resting-state parcellations of pre- and post-fMRI will be completed for personalized targeting and network parcellations.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Targeting the Shared Substrates of Alcohol Misuse and Cognitive Impairment: Accelerated rTMS for Older Adults With Alcohol Use Disorder
- Record updated
- 17 September 2026